ASX Announcements

Neuren announces changes to leadership team
Neuren commences first clinical trial for NNZ-2591
Appendix 4G
Annual Report 2019
Appendix 4C - quarterly
Q1 2020 Activity Report
Corporate presentation, 6 April 2020
First patent in Israel granted for trofinetide
Change of Director's Interest Notice
New international institutional shareholder acquires 14% of Neuren